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Objective 
The etiology of oral verrucous carcinoma is unknown, and human papillomavirus 
‘involvement’ remains contentious. The uncertainty can be attributed to varied detection 
procedures and difficulties in defining ‘gold-standard’ histologic criteria for diagnosing 
‘verrucous’ lesions. Their paucity also hampers investigation. We aimed to analyze oral 
verrucous lesions for human papillomavirus (HPV) subtype genomes. 
Study Design 
We used next-generation sequencing for the detection of papillomavirus sequences, 
identifying subtypes and computing viral loads. We identified a total of 78 oral verrucous 
cases (62 carcinomas and 16 hyperplasias). DNA was extracted from all and sequenced 
at a coverage between 2.5% and 13%. 
Results 
An HPV-16 sequence was detected in 1 carcinoma and 1 hyperplasia, and an HPV-2 
sequence was detected in 1 carcinoma out of the 78 cases, with viral loads of 2.24, 8.16, 
and 0.33 viral genomes per cell, respectively. 
Conclusions 
Our results indicate no conclusive human papillomavirus involvement in oral verrucous 
carcinoma or hyperplasia. 
Statement of Clinical Relevance 
We found that oral verrucous carcinomas and hyperplasias are rarely associated with 
human papillomavirus infection. Our next-generation sequencing methodology allowed 
us to test for all human viruses. We conclude that papillomavirus infections are not 
involved in the development of these tumors. 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in 
the world, with an incidence of about 600 000 cases each year and a 5-year survival rate 
of only about 50%.1 Around half of these cases occur in the oral cavity.2 Most cases 
represent oral squamous cell carcinoma (OSCC), which is found mainly in older men 
exposed to tobacco and alcohol.3 Verrucous carcinoma (VC) is a low-grade variant of 
squamous cell carcinoma (SCC) that rarely presents with distant metastasis.4 
The association between human papillomavirus (HPV) and HNSCC is strongest among 
oropharyngeal squamous cell carcinomas (OPSCC), especially for cancers of the lingual 
and palatine tonsils.5, 6, 7, 8and 9 Furthermore, the risk of developing oropharyngeal 
cancer when adjusted for tobacco and alcohol use is substantially increased with high-
risk HPV oral infections.9 HPV has been identified in 45% to 95% of OPSCC10, 11 and 12 
and is believed to be an etiologic agent.13 In 2012, Kansy et al.14 conducted a systematic 
review encompassing 5338 patients to assess the role of high-risk HPV types in OSCC, 
and 30.1% revealed HPV-positive OSCC samples. Within this review, HPV type 16 was 
identified in 25.4% and type 18 in 18.1%. However, the role of HPV as a causative factor 
was not well defined. 
In general, HPV-positive carcinomas have better prognosis and treatment response than 
HPV-negatives.13, 15 and 16 Studies find a 2- to 3-year overall survival rate of about 60% 
for HPV-negative HNSCC, compared with about 85% for HPV-positives,15 and 16 
indicating the importance of accurate HPV detection and subtyping. 
Oral verrucous carcinoma (OVC) accounts for 2% to 10% of all OSCC cases.17 
‘Verrucous’ terminology is applied to lesions that show exophytic, keratotic surfaces 
made of blunt or sharp epithelial projections, filled with keratin invaginations, but without 
clear fibrovascular cores.18 Histologically, OVC consists of thickened, club-shaped 
papillae and blunt stromal invaginations of well-differentiated squamous epithelium with 
marked keratinization (Figure 1, A, B), with the squamous epithelium lacking cytologic 
criteria of malignancy. OVC invades underlying stroma with a pushing, rather than 
infiltrating, front.19 Oral verrucous hyperplasia (OVH) (Figure 2) and proliferative 
verrucous leukoplakia are both poorly defined but are believed to be histologic 
precursors of OVC and possibly OSCC.20 and 21 Because a verrucous appearance 
suggests a viral etiology, this has prompted a number of investigations for HPV.22 and 23 
Patel et al.24 recently concluded that verrucous carcinomas of the head and neck lacked 
transcriptionally active high-risk human papillomavirus, but they concluded with “our 
study numbers, although relatively generous for a tumor as rare as verrucous carcinoma, 
are still relatively small and may not reflect results on larger cohorts of these tumors.” 
 
 
 
 
 
 
 
 
Fig. 1 
A, Photomicrograph of oral verrucous carcinoma showing ‘extension’ into underlying mucous salivary glands. It 
‘retains’ the bulbous rete seen in verrucous hyperplasia, but clearly has a ‘pushing’ advancing front that now extends 
considerably deeper than adjacent normal epithelium (hematoxylin-eosin, original magnification approximately × 100). 
B, A higher-power view of the deep margin from panel A. Note the lack of nuclear pleomorphism (hematoxylin-eosin, 
original magnification approximately × 400). C, Photomicrograph of p16INK4a immunohistochemical staining of the only 
HPV16-positive, tongue-based OVC identified by NGS. A majority of the nuclei are showing strong positive staining 
(original magnification approximately × 250) (antibody F-12: sc-1661; Santa Cruz Biotechnology Inc; using high-pH 
range settings on Dako Autostainer Link 48; Ely, United Kingdom). (HPV, human papillomavirus; OVC, oral verrucous 
carcinoma; NGS, next-generation sequencing.) 
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Fig. 2. 
A, B, Photomicrograph of oral verrucous hyperplasia showing markedly acanthotic epithelium, with bulbous, club-
shaped papillae lacking significant cellular atypia (A), adjacent to more normal epithelium (B) (A, B, hematoxylin-eosin, 
original magnification approximately ×250). In comparison with Figure 1, the affected epithelium does not show any 
significant ‘deep extension.’ 
Most studies (TableI)23, 25, 26, 27, 28, 29, 30 and 31 relied on polymerase chain reaction (PCR) or 
in situ hybridization for detection and did not identify HPV transcriptional activity markers, 
did not quantitate HPV viral load, or relied on a low sample number. Koskinen et al.32 
reported that 37 of 61 (61%) head and neck cancer samples were positive for HPV and 
that HPV-16 was the most frequently detected type (31 of 37, 84%). 
Table I 
Author Year Lesion 
location 
Diagnosis No. of 
cases 
No. of 
HPV-
positive 
lesions 
HPV 
detection 
method 
Identified 
HPV 
genotypes
VC 7 1/7 Stokes et 
al.25 
2012 Oral 
Dysplastic 
verrucous 
lesions 
13 5/13 
ISH, PCR HPV-16 
Adler-
Storthz et 
al. 26 
1986 Oral VC 9 3/9 ISH HPV-2 
Noble-
Topham et 
al.27 
1993 Oral VC 25 12/25 PCR HPV-6, 11, 
16, 18 
Shroyer et 
al.28  
1993 Oral VC 17 7/17 PCR, ISH HPV-6, 11, 
16, 18, 31, 
33, 35 
Balaram et 
al.29 
1995 Oral VC 15 10/15 PCR HPV-6, 11, 
16, 18 
Mitsuishi et 
al.30 
2005 Oral VC 4 4/4 PCR HPV-2, 18, 
20, 27, 57, 
62, and 
partial 
sequences 
of an 
unknown 
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HPV type 
Fujita et 
al.31 
2008 Oral VC 23 11/23 PCR, ISH HPV-6, 11, 
18, 33, 74 
Head and 
neck 
VC 5 1/5 Del Pino et 
al.23 
2012 
Head and 
neck 
VH 1 0/1 
PCR HPV-35, 
45 
 
The aim of this study was to analyze a large cohort of oral verrucous lesions for the 
presence of HPV subtypes, as well as any other viral genomes, using next-generation 
sequencing (NGS). The cohort included VC and VH but excluded so-called hybrid 
lesions where VC and infiltrative SCC exist,19 as well as lesions with distant metastases, 
as these lesions are not representative of ‘classical’ VC. 
Materials and Methods 
Sample selection 
Of the samples included, 28 were collected from the Pathology Department, St James's 
University Hospital, Leeds, United Kingdom; 16 from the Pathology Division, Queen 
Victoria Hospital, East Grinstead, United Kingdom; 42 from the Pathology Division, 
University of Turin, Italy; and 8 from the Department of Pathology, National Guard 
Hospital, Saudi Arabia. Written informed consent and approval was obtained for all 
patients for the use of their tissue in this research (Leeds Research Ethics Committee 
reference 07/Q1206/30). Verrucous-appearing, but clearly ‘invasive,’ squamous lesions 
were classified as verrucous SCC and excluded.19 
DNA extraction 
Seven 10-μm sections were cut from each block onto plain glass slides. Premalignant or 
malignant areas were microscopically identified and marked on a corresponding 
hematoxylin-eosin-stained slide. Sections were dewaxed and macrodissected with a 
sterile scalpel blade to obtain >70% tumor cell content for DNA isolation, performed 
using Qiagen DNA extraction kits (Qiagen, Sussex, United Kingdom), according to the 
manufacturer's instructions. DNA extraction was successful in 78 cases. 
Determining DNA concentration and purity 
Nucleic acid concentration and purity were measured using the NanoDrop UV 
spectrophotometer NanoDrop-8000 (Thermo Scientific, Wilmington, DE, USA). Besides 
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the concentration, A260:230 and A260:280 ratios were obtained, which are used as 
indicators of the purity of the samples. Double-stranded DNA concentration was 
specifically quantified using the Quant-iT PicoGreen dsDNA BR assay (Invitrogen, 
Paisley, United Kingdom). Of 94 cases, 78 yielded sufficient DNA for library preparation 
and NGS analysis. 
Library preparation and sequencing 
Library preparation for Illumina Genome analyser GAIIx sequencing 
Briefly, between 5 ng and 1 μg of DNA was sheared on a Covaris S2 Sample 
Preparation System (Covaris Inc, Woburn, MA, USA). Sheared DNA samples were 
checked for appropriate size distribution according to the manufacturer's instructions on 
an Agilent Bioanalyser DNA 1000 LabChip (Agilent Technologies Inc, Santa Clara, CA, 
USA). The End-It DNA End-Repair Kit (Epicentre Biotechnologies, Madison, WI, USA) 
was used to convert DNA with damaged ends to blunt-ended, 5′-phosphorylated DNA. 
Klenow DNA polymerase was used to add an A base to each blunt-ended DNA fragment 
so that adapters could be ligated. Six base pairs (bp) of unique oligonucleotide tag 
sequence (adapter) were ligated to the ends of the DNA fragments using methods 
previously published.33 DNA fragments were size selected to 200 bp using magnetic 
beads. DNA was recovered using QiaQuick gel extraction kit (Qiagen, Venlo, 
Netherlands) standard protocols, after which a step comprising 12 enrichment PCR 
cycles was performed. DNA libraries were examined using Invitrogen's Quant-iT 
Picogreen dsDNA BR assay kit and Agilent Bioanalyser DNA 1000 LabChip to assess 
DNA concentration and quality, respectively (Agilent Technologies Inc). Equimolar 
amounts of each DNA library were pooled for cluster amplification and multiplexed up to 
20 samples per lane for 76-bp Illumina single-end sequencing, where each read includes 
6 bp of tagged adapter and 70 bp of genomic DNA sequence. 
Library preparation for Illumina HiSeq 2000 sequencing 
For sequencing using HiSeq 2000, DNA libraries were prepared using NEBNext DNA 
Library Prep Master mix as described for Illumina (New England BioLabs Inc, Hitchin, 
United Kingdom). Between 200 ng and 300 ng of DNA was sheared on a Covaris S2 
Sample Preparation System (Covaris Inc) and checked for appropriate size distribution 
on an Agilent TapeStation D1K High Sensitivity ScreenTape (Agilent Technologies Inc). 
After purification, DNA fragments were end repaired to convert DNA containing damaged 
ends to blunt-ended, 5′-phosphorylated DNA according to the manufacturer's 
instructions. End-repaired DNA fragments were dA-tailed and ligated with the NEBNext 
adaptor. Adaptor-ligated DNA fragments were size selected to 200 bp using magnetic 
beads (Agencourt AMPure; Beckman Coulter Inc, Danvers, MA, USA). Adaptor-ligated 
DNA fragments were tagged to 96 different indexed primers designed by our group 
(Integrated DNA Technologies Inc, Glasgow, United Kingdom) and PCR-enriched using 
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15 enrichment PCR cycles. All reagents used, with the exception of the indexed primers, 
were part of the NEBNext DNA Library Prep Master mix with a NEB adaptor as 
described for Illumina. Libraries were then examined using Invitrogen's Quant-iT 
Picogreen dsDNA BR assay kit and Agilent TapeStation D1K High Sensitivity 
ScreenTape to assess DNA concentration and quality, respectively (Agilent 
Technologies Inc). Samples were pooled, up to 50 samples per lane, and paired-end 
sequenced (2 × 100 bp) on an Illumina HiSeq 2000. 
Data analysis 
Alignment and sequencing 
Reads were split into separate files according to tag and aligned to the human reference 
genome (University of California Santa Cruz version GRCh37/hg19, 
http://genome.ucsc.edu) and to all known viral genomes, including HPV subtypes, 
downloaded from the National Center for Biotechnology Information (http://www-ncbi-
nlm-nih-ov.offcampus.dam.unito.it/genomes/GenomesHome.cgi?taxid%20=%2010239). 
Human genomic copy number analysis 
Human DNA copy number analysis was calculated and analyzed as recently 
described.34 Sample reads were arranged and organized by chromosome and position. 
The ratio of test to control reads was calculated across the genome in equally sized 
windows, averaging 200 tumor reads. A control sample was pooled from a group of 20 
data sets for normal individuals downloaded from the 1000 Genomes Project35 
(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp). 
Viral genomes, HPV subtype detection, and load measurements by sequencing 
Viral load was measured as previously described by Conway et al.36 This technique has 
been found to have good sensitivity and specificity, with the additional benefits of 
providing information on viral subtype and load but also informing genomic copy number. 
The number of reads aligning to the human genome was used to calculate read depth, in 
terms of reads per Kb. (For example, 1 million human reads in a 6-Gb diploid human 
genome equates to 1 read for every 6 Kb of human DNA.) Next, the number of reads 
uniquely aligning to viral genomes was counted. This was equated to a certain number 
of Kb viral sequence per human genome and hence the number of viral genomes per 
human genome. (For example, if 5 HPV reads are detected, and we have previously 
calculated that there is 1 read every 6 Kb, then there is likely to be around 30 Kb of viral 
DNA per cell. This is equivalent to 30/7.9 = 3.8 viral genomes per cell.) We can also 
calculate the probability of detecting 1 copy of the HPV genome per cell, as follows: 
p=1-e (0-(7900-bp viral genomex number of human reads)/6 billion-bp diploid human genome) 
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So a sample with 1 million human reads has a 73% chance of detecting a single copy of 
the HPV genome per cell, whereas a sample with 3 million reads has a 98% chance. 
Higher viral loads will be easier to detect. Given a certain number of human reads, the 
possible viral load that could be detected with 95% confidence is as follows: 
(0-log(1-0,95)x6-Mb diploid human genome)/(7.9-Kb viral genomexnumber of human reads) 
So, for example, only 456 000 reads are needed to detect a load of 5 viral copies per cell 
with 95% confidence. 
We used HPV sequencing data from a previous study (from our group) that included 
positive and negative controls.36 NGS in HPV-positive cases was compared with the 
gold standard of p16 immunohistochemistry (antibody F-12: Sc-1661; Santa Cruz 
Biotechnology Inc) using high-pH range settings on Dako Autostainer Link 48 (Ely, 
United Kingdom) and found to be comparable in sensitivity and specificity. 
Results 
A total of 78 patients, including 41 women and 37 men (mean age, 67 years; range, 38-
96) were included (Table II). Full data are given in Supplemental Table S1, available at 
www.oooojournal.net. Tumor DNA was extracted from a total of 94 samples, and 78 
(83%) of these yielded sufficient DNA for library preparations and NGS. Neither the age 
of the formalin-fixed, paraffin-embedded block nor the amount of tissue sampled 
correlated with low yields. 
Table II.  
Summary of lesion types and patients 
Type of lesion n Age Male Female 
OVC 62 
38-96  
(mean = 67.2) 
33 32 
OVH 16 
52-80  
(mean = 67) 
5 8 
OVH, oral verrucous hyperplasia; OVC, oral verrucous carcinoma. HPV 
Sequencing libraries were prepared from 78 samples. Table III lists the range of human 
and viral reads. HPV-16 sequence was identified in 1 OVH and 1 OVC, and HPV-2 
sequence was detected in 1 OVC out of 78 samples at 95% confidence level with 2.24, 
8.16, and 0.33 viral genomes per cell, respectively. The standard deviation of reads 
taken from all samples was 4 257 556.901 [ranging from 296 655 to 115 682 098]. 
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Table III.  
Viral load determined by next generation sequencing in human oral verrucous 
carcinomas (n = 62) and hyperplasias (n = 16) 
Patient 
ID Species 
Virus 
length 
Human 
reads 
Virus 
reads 
Read 
density 
Kb per 
read 
Kb virus 
sequence 
Viral 
load 
Detectable 
HPV load at 
95% 
confidence 
Probability 
of 
detecting 1 
copy of 
HPV per 
cell 
V-2-2-
C1 
Herpesviru
s 5 235646 296655 1 20.23 20.23 0.09 7.6696 0.3233 
V-2-2-
C1 
Herpesviru
s 1 152261 296655 2 20.23 40.45 0.27 7.6696 0.3233 
V-3-1-A1 - 0 431502 0 13.9 0 0 5.2728 0.4334 
V-4-1-E9 - 0 589117 0 10.18 0 0 3.8621 0.5396 
V-7-1-A Herpesvirus 6A 159322 671946 8 8.93 71.43 0.45 3.3860 0.5872 
V-7-1-A Herpesvirus 1 152261 671946 1 8.93 8.93 0.06 3.3860 0.5872 
V-8-1-C - 0 479578 0 12.51 0 0 4.7443 0.4682 
V-10-1-1 - 0 1556862 0 3.85 0 0 1.4614 0.8712 
V-14-1-6 - 0 1288201 0 4.66 0 0 1.7662 0.8166 
V-15-A3 - 0 1554350 0 3.86 0 0 1.4638 0.8708 
V-19-I4 - 0 1182923 0 5.07 0 0 1.9234 0.7893 
V-20-3 - 0 4253014 0 1.41 0 0 0.5350 0.9963 
V-22-1-4 HPV-16 7905 2368058 7 2.53 17.74 2.24 0.9608 0.9558 
V-23-1-5 - 0 378361 0 15.86 0 0 6.0134 0.3924 
V-25-1- - 0 668260 0 8.98 0 0 3.4047 0.5852 
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Patient 
ID Species 
Virus 
length 
Human 
reads 
Virus 
reads 
Read 
density 
Kb per 
read 
Kb virus 
sequence 
Viral 
load 
Detectable 
HPV load at 
95% 
confidence 
Probability 
of 
detecting 1 
copy of 
HPV per 
cell 
D2 
V-26-1-
A4 - 0 666770 0 8.99 0 0 3.4123 0.5844 
V-29-2-
A3 - 0 840256 0 7.14 0 0 2.7078 0.6692 
V-30-1 Herpesvirus 1 152261 2943604 4 2.04 8.15 0.05 0.7729 0.9793 
V-31-1-
B1 - 0 583436 0 10.28 0 0 3.8997 0.5361 
V-33-1-4 Herpesvirus 6A 159322 1182195 18 5.08 91.36 0.57 1.9246 0.7891 
V-33-1-4 Herpesvirus 6B 162114 1182195 1 5.08 5.08 0.03 1.9246 0.7891 
V-38-1-B - 0 9163412 0 0.66 0 0 0.2483 1.0000 
V-40-1 - 0 7611248 0 0.79 0 0 0.2989 1.0000 
V-41-1-
G - 0 2324407 0 2.58 0 0 0.9788 0.9531 
V-42-1-
G 
Herpesviru
s 1 152261 14884005 6 0.4 2.42 0.02 0.1529 1.0000 
V-44-1-
3J 
Herpesviru
s 1 152261 4793286 2 1.25 2.5 
0.01
6 0.4747 0.9982 
V-46-1-2 Herpesvirus 6B 162114 12047262 150 0.5 74.71 0.46 0.1889 1.0000 
V-60-1 - 0 289026 0 20.76 0 0 7.8721 0.3165 
V-61-1-4 - 0 4901408 0 1.22 0 0 0.4642 0.9984 
  11
Patient 
ID Species 
Virus 
length 
Human 
reads 
Virus 
reads 
Read 
density 
Kb per 
read 
Kb virus 
sequence 
Viral 
load 
Detectable 
HPV load at 
95% 
confidence 
Probability 
of 
detecting 1 
copy of 
HPV per 
cell 
V-62-1-B Herpesvirus 6A 159322 5978774 2 1 2.01 0.13 0.3806 0.9996 
V-63-1-2 - 0 6794116 0 0.88 0 0 0.3349 0.9999 
V-65-1-
D1 - 0 7769042 0 0.77 0 0 0.2929 1.0000 
V-66-1-B - 0 4446770 0 1.35 0 0 0.5117 0.9971 
V-67-1-
B1 - 0 6100026 0 0.98 0 0 0.3730 0.9997 
V-68-1 Herpesvirus 5 235646 2984540 4 2.01 8.04 0.03 0.7623 0.9803 
V-69-1-
D 
Herpesviru
s 5 235646 8960354 2 0.67 1.34 0.01 0.2539 1.0000 
V-70-1-B Herpesvirus 7 153080 6371664 2 0.94 1.88 0.01 0.3571 0.9998 
V-71-1-5 - 0 7896410 0 0.76 0 0 0.2881 1.0000 
V-72-1-4 - 0 6091470 0 0.99 0 0 0.3735 0.9997 
V-73-1 - 0 7774162 0 0.77 0 0 0.2927 1.0000 
V-74-1-A - 0 8256130 0 0.73 0 0 0.2756 1.0000 
V-75-1 - 0 1527565 0 3.93 0 0 1.4895 0.8662 
V-77-1 - 0 7883782 0 0.76 0 0 0.2886 1.0000 
V-78-1-A Herpesvirus 5 235646 6029256 4 0.99 3.98 
0.01
7 0.3774 0.9996 
V-79-1-B Herpesvirus 6B 162114 6483082 2 0.93 1.85 0.01 0.3510 0.9998 
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Patient 
ID Species 
Virus 
length 
Human 
reads 
Virus 
reads 
Read 
density 
Kb per 
read 
Kb virus 
sequence 
Viral 
load 
Detectable 
HPV load at 
95% 
confidence 
Probability 
of 
detecting 1 
copy of 
HPV per 
cell 
V-80-1 - 0 3288128 0 1.83 0 0 0.6920 0.9868 
V-83-1-
C - 0 5666808 0 1.06 0 0 0.4015 0.9994 
V-84-1 - 0 4969566 0 1.21 0 0 0.4578 0.9986 
V-85-1 - 0 5348678 0 1.12 0 0 0.4254 0.9991 
V-86-1 - 0 15107456 0 0.4 0 0 0.1506 1.0000 
V-87-1 - 0 5178734 0 1.16 0 0 0.4393 0.9989 
V-88-1 Herpesvirus 1 152261 6584298 2 0.91 1.82 0.01 0.3456 0.9998 
V-89-1-A - 0 6898174 0 0.87 0 0 0.3298 0.9999 
V-90-1 - 0 4493076 0 1.34 0 0 0.5064 0.9973 
V-91-1 Herpesvirus 1 152261 8733136 2 0.69 1.37 0.01 0.2605 1.0000 
V-92-1 Herpesvirus 1 152261 10556564 4 0.57 2.27 0.02 0.2155 1.0000 
V-94-1 HPV-2 7860 4614998 2 1.3 2.6 0.33 0.4930 0.9977 
V-94-1 Herpesvirus 1 152261 4614998 4 1.3 5.2 0.03 0.4930 0.9977 
V-95-1-B Herpesvirus 1 152261 11163878 4 0.54 2.15 0.01 0.2038 1.0000 
V-95-1-B Herpesvirus 6B 162114 11163878 4 0.54 2.15 0.01 0.2038 1.0000 
V-97-1 - 0 9483722 0 0.63 0 0 0.2399 1.0000 
V-98-1- - 0 7454606 0 0.81 0 0 0.3052 0.9999 
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Patient 
ID Species 
Virus 
length 
Human 
reads 
Virus 
reads 
Read 
density 
Kb per 
read 
Kb virus 
sequence 
Viral 
load 
Detectable 
HPV load at 
95% 
confidence 
Probability 
of 
detecting 1 
copy of 
HPV per 
cell 
D 
V-99-1-4 - 0 6585616 0 0.91 0 0 0.3455 0.9998 
V-100-1-
B - 0 4716241 0 1.27 0 0 0.4824 0.9980 
V-101-1-
F - 0 4412444 0 1.36 0 0 0.5156 0.9970 
V-102-1 - 0 6610388 0 0.91 0 0 0.3442 0.9998 
V-104-
01 
Herpesviru
s 1 152261 10385806 8 0.58 4.62 0.03 0.0114 1.0000 
V-105-
01 
Herpesviru
s 1 152261 10847800 2 0.55 1.10 0.01 0.0109 1.0000 
V-106-
01 - 0 9112970 0 0.66 0 0 0.2497 1.0000 
V-108-
01 - 0 13893548 0 0.43 0 0 0.1638 1.0000 
V-109-T Herpesvirus 4 171823 14969258 6 0.40 2.41 0.01 
0.00698831
8 1.0000 
V-110-
01 - 0 12720402 0 0.47 0 0 0.1789 1.0000 
V-111-
01 - 0 9047886 0 0.66 0 0 0.2515 1.0000 
V-113-T - 0 4086390 0 1.47 0 0 0.5568 0.9954 
V-114-T - 0 7797994 0 0.77 0 0 0.2918 1.0000 
V-115-
01 - 0 15682098 0 0.38 0 0 0.1451 1.0000 
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Patient 
ID Species 
Virus 
length 
Human 
reads 
Virus 
reads 
Read 
density 
Kb per 
read 
Kb virus 
sequence 
Viral 
load 
Detectable 
HPV load at 
95% 
confidence 
Probability 
of 
detecting 1 
copy of 
HPV per 
cell 
V-116-T - 0 10659704 0 0.56 0 0 0.2134 1.0000 
V-118-
01 - 0 15473750 0 0.39 0 0 0.1471 1.0000 
V-120-T - 0 8762276 0 0.68 0 0 0.2597 1.0000 
V-122-
01 - 0 12558750 0 0.48 0 0 0.1812 1.0000 
V-123-T - 0 11502764 0 0.52 0 0 0.1978 1.0000 
V-124-T Herpesvirus 6B 162114 9115790 142 0.66 93.46 0.58 0.0122 1.0000 
V-125-T HPV-16 7905 10041734 108 0.60 64.53 8.16 0.2264 1.0000 
HPV, human papillomavirus. 
Human herpesvirus 
Human herpesvirus (HHV) sequences were detected in 22 of 78 samples (6 OVHs and 
16 OVCs) with viral loads ranging from 0.01 to 0.58 viral genomes per cell (see Table III) 
and with 0.19 viral loads SD. There were 12 samples positive for HHV-1, 1 for HHV-4, 4 
for HHV-5, 5 for HHV-6B, 3 for HHV-6A, and 1 for HHV-7. Four cases had double HHV 
infections (HHV-1 and -5, HHV-1 and -6A, HHV-1 and -6B, and HHV-6A and -6B). 
 
Discussion 
We have described the use of NGS as a validated, powerful, high-throughput method to 
investigate the presence of all characterized human viral genome loads and subtypes, in 
the largest, specifically oral, verrucous sample cohort described to date. Using NGS, 
testing for all HPV subtypes found HPV-16 positivity in only 1 OVH and 1 OVC sample 
and HPV-2 positivity in 1 OVC sample out of 78 oral verrucous lesions with 2.2, 8.1, and 
0.3 viral genomes per cell, respectively. Although it is difficult to accurately predict the 
exact viral load with only a very small number of aligning viral reads, loads in this study 
were much lower than loads in our previous study of HNSCC.36 There the standard 
  15
deviation of the viral loads was 37.7, suggesting that the virus was not contributing to 
disease etiology. We have calculated the probability of detecting a viral load of 1 HPV 
genome per cell, given our read numbers. Of our 78 samples, 60 have sufficient depth to 
detect 1 HPV genome per cell. All but 4 samples have sufficient depth to be able to 
detect 4 copies per cell with 95% confidence. 
HPV DNA may degrade in paraffin-embedded tissues. Sequencing may be less affected 
by this than PCR. The standard PCR test for HPV requires a 120-bp fragment to be 
amplified. We size select our libraries to be around 200 bp to ensure that enough 
fragments of <100 bp are sequenced. If an HPV sequence is in one of these, it would be 
picked up by sequencing but not by PCR. 
The recent article by Patel et al.24 used HPV reverse transcription PCR (RT-PCR) 
testing, but they had a significant subset of cases in which insufficient RNA from the 
formalin-fixed, paraffin-embedded tumor sections precluded HPV RT-PCR testing. 
Nevertheless, they concluded that “active HPV in (head and neck) verrucous carcinomas 
is rare enough to likely be clinically inconsequential.” 
In 2012, del Pino et al.23 investigated the prevalence of HPV in 18 verrucous lesions. 
Using PCR, and finding that only 1 head and neck VC was positive for HPV infection, the 
authors concluded that VC is “unlikely to be related to HPV infection.” In addition, Stokes 
et al.25 studied the role of HPV in malignant and dysplastic oral verrucous lesions and 
suggested that although high-risk HPV DNA was identified in 1 of 7 carcinomas and 5 of 
13 dysplasias, the oncogenic process is not enhanced by HPV oncoproteins, as p16 
overexpression was lacking; they concluded that further work is needed on a larger 
cohort to determine HPV's biologic significance in VC development. 
We have used NGS for the detection of HPV in verrucous samples on the largest cohort 
of oral verrucous carcinomas to date. In addition, we used histologic diagnostic criteria 
defined by the World Health Organization,19 suggesting (unlike Patel et al.24) that oral 
verrucous lesions with frank stromal invasion in the bulk of the tumor should be classified 
as SCCs with verrucous architecture and therefore should be excluded from study. 
Our method using NGS was validated previously (on our control sample set) by detecting 
HPV sequences using PCR and by evaluating p16 expression as a marker for HPV 
infection.36 We found in our previous study that NGS has a high specificity and sensitivity 
for HPV detection when compared with PCR and p16. It has been previously suggested 
that PCR methods can be oversensitive,37 whereas our method can provide better 
specificity, as demonstrated by our observation that all p16-positive samples were also 
positive for HPV-16 by sequencing.36 NGS has also been validated for detecting 
papilloma subtypes and loads not identified by other means in cervical samples.38 
In this study, we searched for all human viruses with sequenced genomes. HHV types 
were detected in one-third of lesions, although they were unconfirmed using any other 
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diagnostic test. NGS tells us nothing about transcriptional activity, so it is not possible to 
speculate further on the clinical significance of this finding. In addition, we scanned the 
control samples used in our previous study36 for all human virus sequences and 
identified 8 positive cases (34.78%). In general, herpes simplex virus–related infections 
are common, affecting approximately two-thirds of adults. Two HHV types known to be 
associated with cancer, Kaposi sarcoma–associated herpesvirus and Epstein-Barr 
virus,39 were not detected. Herpes infection may not be the cause of the disease in our 
patients, but future studies of a similar nature may reveal previously unsuspected 
oncoviruses to be common in a different tumor type. The fact that our read depth is 
enough to detect 1 HPV copy per cell with 95% confidence in most of our samples and a 
modest infection of 5 copies per cell in all but 5, combined with our previous ease of 
detecting HPV in oropharyngeal cancer, confirms that the absence of detection of HPV 
in this large sample is not a technical error but a real biologic finding. 
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Appendix 
Supplemental Table S1.  
Next-generation sequencing analysis for detecting human papillomavirus in oral 
verrucous carcinoma 
Patient ID Sex Age (y) Lesion location Diagnosis
V-2-2-C1 F 60 Mandible and BM OVH 
V-3-1-A1 F 62 Mandible and BM OVH 
V-4-1-E9 M 77 Mandible and BM OVC 
V-7-1-A F 86 Lower lip OVC 
V-8-1-C F 38 FOM OVC 
V-10-1-1 e1 M 62 BM OVC 
V-14-1-6 M 62 BM OVC 
V-15-1-A3 F 75 HP and BM OVH 
V-19-1-I4 F 63 BM OVC 
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Patient ID Sex Age (y) Lesion location Diagnosis
V-20-3 M 54 SP OVC 
V-22-1-4 F 67 BM OVH 
V-23-1-5 F 78 BM OVC 
V-25-1-D2 F 80 Tongue OVH 
V-026-01-A4 M 72 BM OVC 
V-29-2-A3 F 52 HP OVH 
V-30-1 F 80 BM OVH 
V-31-1-B1 M 72 BM OVH 
V-33-01-4 M 72 BM OVH 
V-38-1-B M 63 BM OVC 
V-40-1 F 63 Maxilla OVH 
V-41-1-G M 67 Maxilla OVH 
V-42-1-G F 70 Tongue OVH 
V-44-1-3J M 54 Tongue OVH 
V-46-1-2 M 60 HP OVH 
V-60-1 M 65 Tongue OVC 
V-61-1-4 F 96 Tongue OVC 
V-62-1-B F 73 Tongue OVC 
V-63-1-2 F 66 BM OVC 
V-65-1-D1 M 78 Upper lip OVC 
V-66-1-B M 73 BM OVC 
V-67-1-B1 F 61 FOM OVC 
V-68-1 M 61 BM OVC 
  18
Patient ID Sex Age (y) Lesion location Diagnosis
V-69-1-D M 66 Lower lip and BM OVC 
V-70-1-B M 49 BM OVC 
V-71-1-5 F 82 Mandible OVC 
V-72-1-4 F 82 BM OVC 
V-73-1 F 88 Mandible OVC 
V-74-1-A F 88 HP OVC 
V-75-1 F 49 BM OVC 
V-77-1 M 81 BM OVC 
V-78-1-A M 74 BM OVC 
V-79-1-B F 77 HP/SP OVC 
V-80-1 F 63 Mandible OVC 
V-83-1-C F 72 Mandible and BM OVC 
V-84-1 F 61 BM OVC 
V-85-1 M 73 BM OVC 
V-86-1 M 70 Tongue OVC 
V-87-1 F 53 BM OVC 
V-88-1 M 74 BM OVC 
V-89-1-A M 53 BM OVC 
V-90-1 M 61 BM OVC 
V-91-1 F 60 HP OVC 
V-92-1 M 57 BM OVC 
V-94-1 M 46 BM OVC 
V-95-1-B M 53 BM OVH 
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Patient ID Sex Age (y) Lesion location Diagnosis
V-98-1-D F 85 Tongue OVC 
V-99-1-4 F 81 Tongue OVC 
V-100-1-B M 69 BM OVC 
V-101-1-F F 80 SP OVC 
V-102-1 F 55 BM OVC 
V-104-01 F 78 Tongue OVC 
V-105-01 M 47 Tongue OVC 
V-106-01 F 76 Tongue OVH 
V-108-01 F 78 Tongue OVC 
V-109-T F 82 HP OVC 
V-110-01 F 82 BM OVC 
V-111-01 F 58 Lower lip OVC 
V-112-T F 79 HP OVC 
V-113-T M 64 Maxilla OVC 
V-114-T M 53 Tongue OVC 
V-115-01 M 43 Tongue OVC 
V-116-T M 60 Hard palate/maxilla OVC 
V-118-01 M 58 BM OVC 
V-120-T F 45 BM OVC 
V-122-01 M 76 FOM OVC 
V-123-T M 60 Hard palate/maxilla OVC 
V-124-T M 66 SP OVC 
V-125-T M 64 Tongue OVC 
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BM, buccal mucosa; FOM, floor of mouth; HP, hard palate; SP, soft palate; OVH, oral verrucous 
hyperplasia; OVC, oral verrucous carcinoma. 
Mandible and maxilla refer to alveolus. 
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